Table 1. Patient’s characteristics.
| HCMV+ | |||||
|---|---|---|---|---|---|
| HCMV- n = 39 |
Primary-infection * n = 27 |
Absence of HCMV infection n = 36 |
Reinfection/ Reactivation * n = 19 |
p-value | |
| HCMV serologic status (M12 post transplantation) | |||||
| D-/R-; R- | 28 | / | / | / | |
| D+/R-; R- | 11 | / | / | / | |
| D-R- or D-/R+; R+ | / | 1 | 16 | 10 | |
| D+/R- or D+/R+; R+ | / | 26 | 20 | 9 | |
| Donors | |||||
| Age [years; median (Q1-Q3)] | 44.8 (36.3–55.5) |
56.7 (45.6–64.6) |
49.7 (41.0–58.5) |
57.7 (44.0–64.5) |
0.01021 |
| Gender [Male/Female; (% of Male)] | 26/13 (66.7%) | 12/15 (44.4%) | 18/18 (50.0%) | 11/8 (57.9%) | 0.28742 |
| Donor status [Deceased/Living; (% of deceased donors)] |
39/0 (100.0%) | 26/1 (96.3%) | 36/0 (100.0%) | 18/1 (94.7%) | 0.14262 |
| Recipients | |||||
| Age [years; median (Q1-Q3)] | 45.0 (35.4–54.8) |
49.2 (43.3–66.8) |
56.0 (40.9–63.2) |
57.2 (45.7–61.9) |
0.09601 |
| Gender [Male/Female; (% of Male)] |
24/15 (61.5%) | 21/6 (77.8%) | 24/12 (66.7%) | 10/9 (52.6%) | 0.32752 |
| Transplant [Kidney/Pancreas-Kidney; (% of Kidney only)] |
29/10 (74.3%) | 27/0 (100.0%) | 33/3 (91.7%) | 16/3 (84.2%) | 0.01002 |
| Cold ischemia [minutes; median (Q1-Q3)] |
1086 (813–1463) |
1068 (852–1412) |
1140 (901–1503) |
974 (869–1256) |
0.65361 |
| Serum Creatinine at M12 [μmol/L; median (Q1-Q3)] |
121 (105–140) |
137 (121–170) |
136 (106–171) |
152 (121–175) |
0.13951 |
| Proteinuria at M12 [g/24h; median (Q1-Q3)] |
0.14 (0.11–0.26) |
0.28 (0.12–0.47) |
0.19 (0.11–0.40) |
0.26 (0.16–0.48) |
0.11901 |
| Immunosuppressive regimen [n;(%)] | |||||
| Unknown | 6 (15.4%) | 19 (70.4%) | 6 (16.7%) | 18 (94.7%) | < 0.00013 |
| None | 2 (5.1%) | 0 (0.0%) | 1 (2.8%) | 0 (0.0%) | |
| Basiliximab/Simulect | 18 (46.1%) | 6 (22.2%) | 19 (52.8%) | 0 (0.0%) | |
| (ATG)/Thymoglobulin | 13 (33.3%) | 2 (7.4%) | 10 (27.8%) | 1 (5.3%) | |
| HLA-A*02 recipients¶ [n;(%)] | 27 (69.2%) | 12 (44.4%) | 19 (52.8%) | 9 (47.4%) | 0.17432 |
| Total HLA-I mismatches [n; median (Q1-Q3)] |
3 (2–3.5) | 3 (2.5–4) | 3 (2–3) | 3 (2.5–4) | 0.06521 |
| Total HLA-II mismatches [n; median (Q1-Q3)] |
3 (3–4) | 3 (2–3) | 3 (2–3) | 3 (1–3) | 0.13811 |
| Donor Specific Antibodies (DSA) [n;(%)] | 0 (0.0%) | 1 (3.7%) | 1 (2.8%) | 4 (21.1%) | 0.00792 |
| Post-Tx HCMV infection [n;(%)] | 0 (0.0%) | 27 (100.0%) | / | / | < 0.00012 |
| HCMV infection time post-Tx [months; median (Q1-Q3)] | / | 7 (3–9) | / | 7 (5–10) | 0.85364 |
| Post-Tx HCMV reactivation [n;(% of the HCMV+ recipients)] |
/ | 22 (81.5%) | / | 19 (100%) | 0.06742 |
| HCMV anti-viral prophylaxis [n;(%)] | |||||
| None | 27 (69.2%) | 3 (11.1%) | 2 (5.5%) | 0 (0.0%) | <0.00013 |
| Ganciclovir | 0 (0.0%) | 1 (3.7%) | 0 (0.0%) | 2 (10.5%) | |
| Valganciclovir/Rovalcyte | 12 (30.8%) | 23 (85.2%) | 34 (94.4%) | 17 (89.5%) | |
D: Donor; R: Recipient
1 Kruskall-Wallis test
2 Fisher’s exact test
3 Pearson’s chi-squared test
4 Mann Whitney test
¶ transplant recipients carrying at least one HLA-A*02 allele
*Definitions of Cytomegalovirus infection [35]